Physician profile
Lynn E Boler
NPI 1801906219
$3,217.75
in general payments reported to CMS, 2019-2025
15 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $320 · 2021: $631 · 2022: $512 · 2023: $498 · 2024: $526 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.44 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $681.18 | 2019-2024 | Argos, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $470.01 | 2022-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Allergan, INC. | $329.73 | 2019-2022 | |
| Abbvie INC. | $319.28 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $266.40 | 2019-2021 | |
| Ocular Therapeutix, INC. | $232.69 | 2019-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $208.10 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $194.54 | 2024-2025 | Xdemvy |
| Astellas Pharma US INC | $189.14 | 2024-2025 | Izervay |
| Amgen INC. | $88.58 | 2024 | Tepezza |
| Novartis Pharmaceuticals Corporation | $86.22 | 2021-2023 | |
| Oyster Point Pharma, INC. | $69.28 | 2023-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $40.48 | 2019-2020 | |
| Biotissue Holdings INC. | $25.73 | 2025 | |
| Eyepoint US, INC. | $16.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Boler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.